Despite the firm again raising its revenue and GAAP guidance, we’ve made only minor changes to our model in the long run.

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

The FDA has set a new PDUFA date for AXS-07 on ... target CGRP (calcitonin gene-related peptide); examples - Ubrogepant (Ubrelvy) Rimegepant (Nurtec ODT); b) Ditans, newer molecules targeting ...

Several other key products also delivered double-digit sales growth, including Venclexta, Vraylar, Ubrelvy, and Qulipta ...

and it should be driven by the two migraine drugs Ubrelvy and Qulipta, and also by continued growth of Vraylar and the Botox therapeutic. Vyalev (ABBV-951) was finally approved by the FDA last ...

In the third quarter, top-line growth is expected to have been driven by exceptional demand growth for Lilly’s FDA-approved tirzepatide ... from newer drugs like Ubrelvy, Elahere, Epkinly ...

When migraine patients visit AbbVie’s website for Ubrelvy (ubrogepant), a button in the top-right ... Pfizer is marketing Nurtec ODT (rimegepant), a migraine medication approved by the FDA that had ...

The FDA has approved three CGRP inhibitors, collectively called gepants, for the acute treatment of migraine with or without aura: Rimegepant (Nurtec ODT) Ubrogepant (Ubrelvy) Zavegepant (Zavzpret) ...

In February 2024, the U.S. FDA approved Aurlumyn (iloprost), an injectable vasodilator treatment that is the first ever to be approved for the treatment of severe frostbite. This approval was ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...